Could Anivive's FIP Drug Treat COVID-19? Drs. Dave Bruyette, Chad Dodd, and CEO Dylan Balsz

Could an experimental Feline Infectious Peritonitis (FIP) drug be the secret to treating human COVID-19? 

This week we’re thrilled to bring you an exclusive interview with the California-based Anivive Lifesciences team to discuss their recent FDA submittal to use their experimental FIP drug on human coronavirus patients.

Anivive’s Founder & CEO, Mr. Dylan Balsz joins us along with Dr. David Bruyette, Chief Medical Officer, and Dr. Chad Dodd, Chief Commercial Officer to share their exciting story.

Hosts Dr. Ernie Ward and Beckie Mossor, RVT learn about how a companion animal drug company’s deep research and experience with coronaviruses is helping develop an advanced treatment for for humans suffering from COVID-19.

This conversation emphasizes the importance of the One Health concept, how veterinarians are uniquely poised to tackle pandemics, and the exciting prospects for using software to accelerate biotechnologies and usher in medical breakthroughs for both humans and animals.   

And Dr. Dave Bruyette. Anytime you have the chance to learn from Dr. Bruyette, don't pass it up!  

For more information, visit  https://www.anivive.com/